Ultragenyx Pharmaceutical
RARE
254 hedge funds and large institutions have $7.73B invested in Ultragenyx Pharmaceutical in 2021 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 88 increasing their positions, 98 reducing their positions, and 35 closing their positions.
163% more call options, than puts
Call options by funds: $47.3M | Put options by funds: $17.9M
20% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 35
1% more funds holding
Funds holding: 252 → 254 (+2)
0.84% less ownership
Funds ownership: 102.28% → 101.44% (-0.84%)
10% less repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 98
17% less capital invested
Capital invested by funds: $9.36B → $7.73B (-$1.63B)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$164M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$59.6M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$51.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$32.5M |
| 5 |
HM
HealthCor Management
New York
|
+$28.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$114M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$50.1M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$49.4M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$27.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$26.4M |
RARE Hedge Fund Activity: Q1 2021 in Review
254 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2021, worth a combined $7.73B — down 17% from $9.36B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new RARE positions and 35 closed out — a net gain of 7 holders — while 88 added to existing stakes and 98 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $164M. The largest seller was Capital International Investors, cutting an estimated $114M.
- 254 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2021, up from 252 in Q4 2020.
- Funds reported $7.73B of Ultragenyx Pharmaceutical stock for Q1 2021, down 17% quarter-over-quarter.
- 42 funds opened new Ultragenyx Pharmaceutical positions in Q1 2021 and 35 closed out, a net change of +7 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q1 2021 was T. Rowe Price Associates, an estimated $164M added.
- The largest Ultragenyx Pharmaceutical seller in Q1 2021 was Capital International Investors, an estimated $114M sold.
Based on aggregated 13F filings for Q1 2021.